Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
6
CNSP Quote, Financials, Valuation and Earnings
Last price:
$3.67
Seasonality move
:
-35.71%
Day range:
$3.63 - $4.23
52-week range:
$3.63 - $114.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.23x
Volume:
33K
Avg. volume:
57.7K
1-year change:
-94.5%
Market cap:
$2.3M
Revenue:
--
EPS (TTM):
-$40.72
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CNSP
CNS Pharmaceuticals, Inc.
|
-- | -- | -- | -- | $20.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 110.49% | -58.59% | $479.79 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835.5M | $0.67 | 11.91% | 37.43% | $89.09 |
|
IMNN
Imunon, Inc.
|
-- | -$1.82 | -- | -269.06% | $21.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CNSP
CNS Pharmaceuticals, Inc.
|
$3.63 | $20.00 | $2.3M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.47 | $31.21 | $3.8B | 14.46x | $0.00 | 0% | 3.61x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$322.28 | $479.79 | $42.6B | 1,340.04x | $0.00 | 0% | 13.22x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$60.31 | $89.09 | $11.6B | 22.60x | $0.00 | 0% | 3.82x |
|
IMNN
Imunon, Inc.
|
$3.42 | $21.50 | $7.3M | -- | $0.00 | 0% | 16.43x |
|
SVRA
Savara, Inc.
|
$5.35 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CNSP
CNS Pharmaceuticals, Inc.
|
0.31% | 4.348 | 0.6% | 5.04x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.064 | 4.61% | 2.37x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
IMNN
Imunon, Inc.
|
21.26% | 5.236 | 10.13% | 1.25x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CNSP
CNS Pharmaceuticals, Inc.
|
-$700 | -$3.3M | -147.68% | -150.13% | -- | -$2.2M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
CNS Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns CNSP or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to CNS Pharmaceuticals, Inc.'s net margin of 25.76%. CNS Pharmaceuticals, Inc.'s return on equity of -150.13% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital CNSPCNS Pharmaceuticals, Inc.-- -$5.76 $9.9M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About CNSP or ACAD?
CNS Pharmaceuticals, Inc. has a consensus price target of $20.00, signalling upside risk potential of 450.96%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 38.9%. Given that CNS Pharmaceuticals, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe CNS Pharmaceuticals, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CNSPCNS Pharmaceuticals, Inc.0 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is CNSP or ACAD More Risky?
CNS Pharmaceuticals, Inc. has a beta of 0.505, which suggesting that the stock is 49.524% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock CNSP or ACAD?
CNS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CNS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNSP or ACAD?
CNS Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. CNS Pharmaceuticals, Inc.'s net income of -$3.2M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, CNS Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 14.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CNS Pharmaceuticals, Inc. is -- versus 3.61x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNSPCNS Pharmaceuticals, Inc.-- -- -- -$3.2M ACADACADIA Pharmaceuticals, Inc.3.61x 14.46x $278.6M $71.8M
-
Which has Higher Returns CNSP or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to CNS Pharmaceuticals, Inc.'s net margin of 20.1%. CNS Pharmaceuticals, Inc.'s return on equity of -150.13% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital CNSPCNS Pharmaceuticals, Inc.-- -$5.76 $9.9M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About CNSP or ALNY?
CNS Pharmaceuticals, Inc. has a consensus price target of $20.00, signalling upside risk potential of 450.96%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $479.79 which suggests that it could grow by 48.87%. Given that CNS Pharmaceuticals, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe CNS Pharmaceuticals, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CNSPCNS Pharmaceuticals, Inc.0 0 0 ALNYAlnylam Pharmaceuticals, Inc.13 8 0 -
Is CNSP or ALNY More Risky?
CNS Pharmaceuticals, Inc. has a beta of 0.505, which suggesting that the stock is 49.524% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock CNSP or ALNY?
CNS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CNS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNSP or ALNY?
CNS Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. CNS Pharmaceuticals, Inc.'s net income of -$3.2M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, CNS Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,340.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CNS Pharmaceuticals, Inc. is -- versus 13.22x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNSPCNS Pharmaceuticals, Inc.-- -- -- -$3.2M ALNYAlnylam Pharmaceuticals, Inc.13.22x 1,340.04x $1.2B $251.1M
-
Which has Higher Returns CNSP or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to CNS Pharmaceuticals, Inc.'s net margin of -3.91%. CNS Pharmaceuticals, Inc.'s return on equity of -150.13% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital CNSPCNS Pharmaceuticals, Inc.-- -$5.76 $9.9M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About CNSP or BMRN?
CNS Pharmaceuticals, Inc. has a consensus price target of $20.00, signalling upside risk potential of 450.96%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $89.09 which suggests that it could grow by 47.72%. Given that CNS Pharmaceuticals, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe CNS Pharmaceuticals, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CNSPCNS Pharmaceuticals, Inc.0 0 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is CNSP or BMRN More Risky?
CNS Pharmaceuticals, Inc. has a beta of 0.505, which suggesting that the stock is 49.524% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock CNSP or BMRN?
CNS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CNS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNSP or BMRN?
CNS Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. CNS Pharmaceuticals, Inc.'s net income of -$3.2M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, CNS Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 22.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CNS Pharmaceuticals, Inc. is -- versus 3.82x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNSPCNS Pharmaceuticals, Inc.-- -- -- -$3.2M BMRNBioMarin Pharmaceutical, Inc.3.82x 22.60x $786.8M -$30.7M
-
Which has Higher Returns CNSP or IMNN?
Imunon, Inc. has a net margin of -- compared to CNS Pharmaceuticals, Inc.'s net margin of --. CNS Pharmaceuticals, Inc.'s return on equity of -150.13% beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital CNSPCNS Pharmaceuticals, Inc.-- -$5.76 $9.9M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About CNSP or IMNN?
CNS Pharmaceuticals, Inc. has a consensus price target of $20.00, signalling upside risk potential of 450.96%. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 528.66%. Given that Imunon, Inc. has higher upside potential than CNS Pharmaceuticals, Inc., analysts believe Imunon, Inc. is more attractive than CNS Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CNSPCNS Pharmaceuticals, Inc.0 0 0 IMNNImunon, Inc.3 1 0 -
Is CNSP or IMNN More Risky?
CNS Pharmaceuticals, Inc. has a beta of 0.505, which suggesting that the stock is 49.524% less volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.135, suggesting its more volatile than the S&P 500 by 113.504%.
-
Which is a Better Dividend Stock CNSP or IMNN?
CNS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CNS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNSP or IMNN?
CNS Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Imunon, Inc. quarterly revenues of --. CNS Pharmaceuticals, Inc.'s net income of -$3.2M is higher than Imunon, Inc.'s net income of -$3.4M. Notably, CNS Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CNS Pharmaceuticals, Inc. is -- versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNSPCNS Pharmaceuticals, Inc.-- -- -- -$3.2M IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns CNSP or SVRA?
Savara, Inc. has a net margin of -- compared to CNS Pharmaceuticals, Inc.'s net margin of --. CNS Pharmaceuticals, Inc.'s return on equity of -150.13% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital CNSPCNS Pharmaceuticals, Inc.-- -$5.76 $9.9M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About CNSP or SVRA?
CNS Pharmaceuticals, Inc. has a consensus price target of $20.00, signalling upside risk potential of 450.96%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 102.1%. Given that CNS Pharmaceuticals, Inc. has higher upside potential than Savara, Inc., analysts believe CNS Pharmaceuticals, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CNSPCNS Pharmaceuticals, Inc.0 0 0 SVRASavara, Inc.6 0 0 -
Is CNSP or SVRA More Risky?
CNS Pharmaceuticals, Inc. has a beta of 0.505, which suggesting that the stock is 49.524% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock CNSP or SVRA?
CNS Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CNS Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CNSP or SVRA?
CNS Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. CNS Pharmaceuticals, Inc.'s net income of -$3.2M is higher than Savara, Inc.'s net income of -$29.6M. Notably, CNS Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CNS Pharmaceuticals, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CNSPCNS Pharmaceuticals, Inc.-- -- -- -$3.2M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
